Content deleted Content added
Citation bot (talk | contribs) Add: pages, issue, volume, journal, date, title, authors 1-4. | Use this bot. Report bugs. | Suggested by Marbletan | #UCB_webform |
consistent citation formatting |
||
| (One intermediate revision by one other user not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
| verifiedrevid = 443857623
Line 7 ⟶ 8:
<!--Clinical data-->
| tradename = S.T.37, Crystoids<ref>{{cite web |title=Hexylresorcinol |url=https://webbook.nist.gov/cgi/cbook.cgi?ID=136-77-6 |website=NIST Chemistry WebBook, SRD 69 |publisher=NIST |access-date=19 April 2024}}</ref>
| Drugs.com = {{drugs.com|international|hexylresorcinol}}
| pregnancy_category =
Line 51 ⟶ 52:
As an [[antiseptic]], it is marketed as '''S.T.37''' by Numark Laboratories, Inc. (in a 0.1% solution) for oral pain relief and as a topical antiseptic. It is available for use topically on small [[skin infection]]s or as an ingredient in [[throat lozenge]]s.
As an [[anthelmintic]], 4-hexylresorcinol was sold under the brand Crystoids.<ref>{{
Sytheon Ltd., USA markets 4-hexylresorcinol (trade named Synovea HR).
Line 62 ⟶ 63:
In mice with cancer, 4-hexylresorcinol inhibited [[NF-κB]] and extended their survival rate.<ref>{{cite journal | vauthors = Kim SG, Lee SW, Park YW, Jeong JH, Choi JY | title = 4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells | journal = Oncology Reports | volume = 26 | issue = 6 | pages = 1527–32 | date = December 2011 | pmid = 21874263 | doi = 10.3892/or.2011.1436 | doi-access = free }}</ref>
4-Hexylresorcinol can be used in the synthesis of [[tetrahydrocannabihexol]]<ref>{{cite journal | doi = 10.1021/ja01255a061 | title = Tetrahydrocannabinol Homologs and Analogs with Marihuana Activity. XIII<sup>1</sup> | date = 1942 |
== References ==
{{Reflist}}
{{Throat preparations}}
| |||